Cytuvax
Oxfordlaan 55
Maastricht
6229 EV
Tel: 31-433881424
Website: http://www.cytuvax.com/
Email: info@cytuvax.com
About Cytuvax
CyTuVax was founded in Maastricht in 2012 by dr. René Vleugels and prof. dr. Frank W. Falkenberg. The company has developed a platform vaccination technology consisting of cytokines aggregates as powerful immune stimulators (adjuvant).YEAR FOUNDED:
2012
LEADERSHIP:
Founders: René Vleugels and Frank W. Falkenberg
Founder and CEO: René Vleugels
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
All Products
5 articles about Cytuvax
-
BioSpace Global Roundup, June 20
6/20/2019
Biotech and pharma companies from across Europe and Asia share company and pipeline updates. -
Phase 2 Trial Shows Efficacy of CyTuVax’s Adjuvant Platform Technology
6/17/2019
This trial focused on so-called non-responders to hepatitis B vaccination
-
Cytuvax Starts Its Phase II BE RESPONDER! Study Effective Vaccination For Hepatitis B Non-Responders
3/14/2017
-
Cytuvax Starts Its Phase II BE RESPONDER! Study Effective Vaccination For Hepatitis B Non-Responders
3/8/2017
-
Cytuvax Reports Interim Results Of The Phase I Clinical Trial With The HBAI20 Hepatitis B Vaccine For Non-Responders
4/29/2016